Korea's Health Ministry Dismisses Likelihood Of Compulsory Licensing For Antivirals Tamiflu and Relenza
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The South Korean government is not in a "desperate position" that would justify seeking compulsory licensing to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) in a protracted battle against A/H1N1, the health ministry said